Tara K. Iyer, MD

Panelists discuss how advancing NK receptor research is reshaping menopause care, emphasizing education, innovation, and patient empowerment for lasting impact.

Panelists discuss how structured monitoring and interdisciplinary collaboration enable safe, effective integration of NK-targeted therapies into primary care.

Panelists discuss how NK receptor antagonists can be strategically positioned as core nonhormonal options within the broader VMS treatment landscape.

Panelists discuss how NK receptor antagonism may improve mood and sleep quality, linking thermoregulation with broader emotional and cognitive health benefits.

Panelists discuss how NK1 receptor antagonists show promise beyond VMS, suggesting wider therapeutic potential across neurological and systemic conditions.

Panelists discuss how NK receptor antagonists deliver fast symptom relief with strong safety profiles, improving adherence and clinical confidence in their use.

Panelists discuss how elinzanetant offers a safe, effective nonhormonal option for managing VMS in women receiving endocrine therapy for breast cancer.

Panelists discuss how elinzanetant demonstrates strong efficacy and safety across trials, reinforcing neurokinin modulation as a viable core treatment for VMS.

Panelists discuss how dual NK3/NK1 receptor antagonism may expand therapeutic benefits by targeting multiple neural pathways involved in VMS and mood regulation.

Panelists discuss how NK3 receptor antagonism through fezolinetant offers effective, rapid relief from VMS with a strong safety profile and nonhormonal benefits.

Panelists discuss how NK receptor antagonism provides a targeted, nonhormonal strategy that addresses the physiological root of vasomotor symptoms.

Panelists discuss how limited treatment options and systemic barriers underscore the urgent need for accessible, targeted therapies for vasomotor symptoms.

Panelists discuss how vasomotor symptoms undermine physical comfort, sleep, and long-term health, emphasizing integrative management to restore overall quality of life.

Panelists discuss how hormonal decline and KNDy neuron overactivation drive vasomotor symptoms and inform the development of targeted neurokinin receptor therapies.

Panelists discuss how providers should actively screen for vasomotor symptoms (VMS), especially given the lengthy wait times to see specialists, emphasizing that education for both patients and health care providers is essential for timely intervention and effective management.

Panelists discuss how there is no change in therapeutic indication based on this particular finding, though it may serve as a beneficial side effect for patients struggling with sleep difficulties.

Panelists discuss how long-term safety data for fezolinetant and elinzanetant remain unavailable, though short-term results show very positive outcomes with significantly higher efficacy than previous treatment options.

Panelists discuss how fezolinetant and elinzanetant can cause liver-related adverse events requiring careful monitoring for drug-induced liver injury, noting that patients typically recover after discontinuation and emphasizing that primary providers are ideally positioned to manage patients with complex comorbidities.

Panelists discuss how emerging therapies demonstrate promising efficacy data while highlighting the adverse metabolic and cardiovascular consequences associated with untreated vasomotor symptoms (VMS).

Panelists discuss how emerging therapies demonstrate promising efficacy data while highlighting the adverse metabolic and cardiovascular consequences associated with untreated vasomotor symptoms (VMS).

Panelists discuss how previous therapies lacked efficacy for vasomotor symptoms, while new treatments fezolinetant and elinzanetant offer superior effectiveness, with elinzanetant specifically addressing additional symptoms beyond the primary condition.

Panelists discuss how vasomotor symptoms (VMS) can persist for years with variable manifestations, significantly disrupting both social and professional spheres, resulting in multibillion-dollar economic losses through decreased productivity and increased insurance costs.